The stock's fall snapped a two-day winning streak.

Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...

Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools ...

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...